CN104023734A - Composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as active ingredient - Google Patents
Composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as active ingredient Download PDFInfo
- Publication number
- CN104023734A CN104023734A CN201280061440.7A CN201280061440A CN104023734A CN 104023734 A CN104023734 A CN 104023734A CN 201280061440 A CN201280061440 A CN 201280061440A CN 104023734 A CN104023734 A CN 104023734A
- Authority
- CN
- China
- Prior art keywords
- water extract
- pleurotus ferulae
- ferulae lanzi
- extract
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000006521 Pleurotus eryngii var ferulae Nutrition 0.000 title claims abstract description 74
- 244000088486 Pleurotus eryngii var. ferulae Species 0.000 title claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 235000013305 food Nutrition 0.000 claims description 28
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 23
- 239000004615 ingredient Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 235000013361 beverage Nutrition 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 230000007935 neutral effect Effects 0.000 abstract description 6
- 108010055297 Sterol Esterase Proteins 0.000 abstract 1
- 102000000019 Sterol Esterase Human genes 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 26
- 230000006870 function Effects 0.000 description 15
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940040461 lipase Drugs 0.000 description 5
- 235000019421 lipase Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001906 cholesterol absorption Effects 0.000 description 4
- -1 compound vitamin Chemical class 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 3
- 244000252132 Pleurotus eryngii Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010001394 Disaccharidases Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000001462 Pleurotus ostreatus Species 0.000 description 2
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 235000008446 instant noodles Nutrition 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NBUIHPSOROJZRE-UHFFFAOYSA-N C(CCC)(=O)O.[N+](=O)([O-])C1=CC=C(C=C1)C(C1=CC=CC=C1)=O Chemical compound C(CCC)(=O)O.[N+](=O)([O-])C1=CC=C(C=C1)C(C1=CC=CC=C1)=O NBUIHPSOROJZRE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000510609 Ferula Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The present invention relates to a composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as an active ingredient, and a dietary supplement containing the same. The water extract of Pleurotus eryngii var. ferulae is superior to an ethanol extract thereof in suppressing the activity of cholesterol esterase and absorbing neutral fats.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and healthy accesary foods compositions of the water extraction containing Pleurotus ferulae Lanzi, it can be take prevention or treatment hyperlipemia and uses as object.
Background technology
Hyperlipemia refers to the state that the fat constituent in blood is too high.Conventionally T-CHOL surpasses 240mg/dl, or neutral fat is that 200mg/dl is called hyperlipemia when above.Cholesterol piece artery-clogging in hyperlipemia, hinder blood circulation, thereby it is considered to bring out the main cause of hypertension, myocardial infarction, apoplexy.The hyperlipidemia patient quantity of Korea S just continues to increase, and in world wide, hyperlipidemia patient also has increase, and therefore anticipation can cause more hyperlipidemia patient in the future.Therefore, the multiple research of the open treatment for hyperlipemia and prevention method, prescription method.
The dysbolismus that the reason of generation hyperlipemia is being caused by inherited genetic factors, but at the too high diet of heat with lack motion and the other reasonses such as obesity that cause also can cause blood inner cholesterol to be accumulated and (Bray GA, Popkin BM.:Dietary fat intake dose affec t obesity.Am.J Clin.Nutr68:1157-1173 (1998)) occur.The picked-up to food rich in fat particularly causing due to the recipe in west increases, and is considered to cause the main cause of hyperlipemia.At present, in worldwide, in order to prevent or treat hyperlipemia, just carrying out a large amount of exploitations to candidate's functional mass such as cholesterol absorption inhibitors, the attention rate of meanwhile resisting hyperlipemia functional evaluation model also increases gradually.
At present, in the medicine for the treatment of hyperlipemia, the drug use of Pitavastatin (statin) class is the most extensive.This type of medicine has the effect that suppresses cholesterol biosynthesis and reduce low-density (LDL)-cholesterol in blood as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor.In addition, main or with ezetimble (ezetimibe), nicotinic acid (nia cin) and Bei Te (bibrate) preparation etc., but have once in a while the probability of the side effect such as myalgia, constipation or even gastricism and hepatic insufficiency occur during administration.
Approximately more than 10,000 kind of mushroom found in the whole world, and it is edible and medical value is very high.Therefore,, for guaranteeing microorganism useful resources, the advanced countries such as European Union, the U.S., Japan are carrying out large quantity research to it.Particularly have a lot of research reports to point out, the biological active substances side effect that mushroom produces is less, therefore very safe aspect toxicity, and has the several functions such as function adjusting to human immune system, anticancer effect, adjusting metabolism.
The inventor has carried out repeatedly to being almost free from side effects in vivo, and can absorb and have the natural materials that improves hyperlipemia effect and carry out large quantity research by suppressing body inner cholesterol, thereby has started research of the present invention.
Above-mentioned Pleurotus ferulae Lanzi (Pleurotus eryngii var.ferulea (Pf.)) is the mutation of Pleurotus eryngii.English name is Ferula Oyster Mushroom, may be interpreted as the Pleurotus ostreatus of Resina Ferulae tree.In China, being also referred to as is that Bai Ling picks up the ears.It is in the dry area of China, and the Resina Ferulae of Xinjiang region tree is upper wild, and growth temperature is the middle temperature of 8-20 ℃, therefore in Korea S, is adapted at cultivating in spring, autumn.
From be born in China and the Pleurotus ferulae Lanzi in the Central Asia be considered to can blood stasis dispelling, antitussive and antiinflammatory, and still to the resultful medicinal food of gastrointestinal disease tool.And in Korea Spro's medical book, it is described as is to have to get rid of vivotoxin, cough-relieving, antiinflammatory and to the effective high functionality mushroom of gynaecopathia.
The inventor is in order to seek the natural materials of the medicines such as alternative Pitavastatin class, and in the process that the inhibitor that maybe can reduce Blood Cholesterol to can suppress heavily absorbing of cholesterol and neutral fat in small intestinal is studied repeatedly, confirmed Pleurotus ferulae Lanzi extract, especially the water extract of Pleurotus ferulae Lanzi can effectively suppress the absorption of Blood Cholesterol and neutral fat, thereby has completed the present invention.
Summary of the invention
Goal of the invention
The object of the invention is to, provide a kind of containing to cause hardly in vivo side effect, and can be used for suppressing the compositions of the Pleurotus ferulae Lanzi water extract that body inner cholesterol and neutral fat absorb; And contain said composition as effective ingredient for preventing or treat pharmaceutical composition and the healthy functions food of hyperlipemia.
Technical scheme
For achieving the above object, the present invention has obtained the water extract of Pleurotus ferulae Lanzi, has verified that it improves the effect of hyperlipemia, and evaluate it as test material.
Beneficial effect
Of the present invention containing Pleurotus ferulae Lanzi water extract as the compositions of effective ingredient, by suppressing the absorption of body inner cholesterol and neutral fat, can be effectively for preventing or treat the excellent effect of hyperlipemia thereby have.
Accompanying drawing explanation
Fig. 1 is for representing the relatively active curve chart that suppresses effect of CEL of the Pleurotus ferulae Lanzi extract of embodiments of the invention and comparative example.
Fig. 2 is for representing relatively according to the curve chart of the CEL activity of the concentration of the Pleurotus ferulae Lanzi water extract of the embodiment of the present invention.
Fig. 3 is for representing relatively according to the curve chart of the TGL activity of the concentration of the Pleurotus ferulae Lanzi water extract of the embodiment of the present invention.
Fig. 4, for what represent relatively according to the Pleurotus ferulae Lanzi water extract of the embodiment of the present invention and existing fat suppression agent orlistat (Orlistat), absorbs cholesterol to the curve chart of the absorbtivity of blood from digestive tube.
Preferred forms
Pleurotus ferulae Lanzi water extract can be prepared according to the preparation method of common plant extract.The most preferably, under 15 ℃ of conditions, to pulverizing after above-mentioned Pleurotus ferulae Lanzi cool-drying, remove afterwards residue, add 0.1 to 20g above-mentioned ground product in every 100mL water, most preferably every 100mL extracts in solvent and adds 1 to 5g to extract.Do not advise adopting 40 ℃ of above hot air dryings.And, when too low than the content that extracts solvent Pleurotus ferulae Lanzi ground product, cannot give full play to the effect of absorption cholesterol of Pleurotus ferulae Lanzi and not preferred; And than extracting its content of solvent when too much, along with the increase of its effect of increase of content not obvious, producing cost can increase, therefore from the viewpoint of productivity, not preferred.
The extraction conditions of Pleurotus ferulae Lanzi is preferably, and Pleurotus ferulae Lanzi, with after water as extracting solvent mixes, is extracted 12 to 36 hours under 20 to 60 ℃ of temperature conditions; Most preferably be, under 30 to 40 ℃ of temperature conditions, extract 20 to 24 hours.
While extracting under the cryogenic conditions below 20 ℃, in order minute to extract being effectively extracted into, need long-time; And while extracting under more than 60 ℃ temperature conditions, its activity decreased, therefore not preferred.The water extract that particularly carries out more than 15 minutes hot water extraction under 100 ℃ of conditions does not have activity, therefore cannot use.
And, will shorten to 12 hours extraction time when following, the concentration of the effective ingredient extracting is low; And while extracting 36 hours above time, the increase of the effective ingredient concentration extracting producing along with the increase of extraction time is very micro-, therefore from the viewpoint of productivity, not preferred.
And preferably, the water extract of the Pleurotus ferulae Lanzi extracting by said method, after utilizing filter cloth etc. to filter, carries out centrifugalize to filtrate, removes after precipitation, carries out concentrating under reduced pressure or concentrated, and carries out using after lyophilization.
And, being used for the treatment of or preventing in the compositions of hyperlipemia of above-mentioned embodiment, as the water extractable content of the Pleurotus ferulae Lanzi of effective ingredient, be preferably 0.01 to 30 % by weight.As the water extractable content of the Pleurotus ferulae Lanzi of effective ingredient during lower than 0.01 % by weight, that suppresses that body inner cholesterol absorbs has little effect; And content is while surpassing 30 % by weight, the reinforced effects of the inhibition activity occurring according to the increase of content is very micro-, therefore economical not.In compositions, the water extractable content of Pleurotus ferulae Lanzi is preferably 0.001 to 50 % by weight, most preferably is 0.1 to 30 % by weight.
Another embodiment according to the present invention, provides a kind of for preventing or treat the medicine of hyperlipemia, and the water extraction that wherein above-mentioned medicine contains Pleurotus ferulae Lanzi contained in above-mentioned composition is as effective ingredient.The above-mentioned water extract that contains Pleurotus ferulae Lanzi, as the medicine of effective ingredient, can further comprise and be generally used for suitable carrier, excipient and diluent prepared by medicine.
In the present invention, can be contained in the water extract that contains Pleurotus ferulae Lanzi has lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltose alcohol, starch, arabic gum, alginate, gelatin, calcium phosphate, calcium silicates, cellulose, methylcellulose, microcrystalline Cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, Talcum, magnesium stearate and mineral oil as the carrier in the medicine of effective ingredient, excipient and diluent.
The water extract that contains Pleurotus ferulae Lanzi of the present invention, as the medicine of effective ingredient, can adopt respectively usual way to be prepared into the peroral dosage forms such as powder, granule, tablet, suspending agent, Emulsion, syrup.
Above-mentioned peroral dosage form thing refers to for the solid preparation of oral administration and liquid phase preparation, for the solid preparation of oral administration can comprise tablet, pill, powder, granule, capsule etc., and these solid preparations can be prepared by the excipient that mixes at least more than one in said extracted thing, above-mentioned excipient is such as can be calcium carbonate (calcium carbonate), sucrose (sucr ose) or lactose (lactose), gelatin etc.
And, except simple excipient, also can use the lubricants such as magnesium stearate, Talcum.Aqueous preparation for oral administration can be suspending agent, mixture for internal use, Emulsion, syrup etc., can comprise normally used such as outside the simple diluent such as water, liquid paraffin, also can contain multiple other excipient, such as wetting agent, sweeting agent, aromatic, preservative agent etc.
The preferred dosage of the pharmaceutical composition that contains Pleurotus ferulae Lanzi water extract of the present invention factor and the difference such as during according to degree, drug form, route of administration and the administration of state and body weight, disease, but can carry out suitable selection by those skilled in the art.Preferably, the Pleurotus ferulae Lanzi water extract that contains of the present invention is as the medicine of effective ingredient, and the amount of Pleurotus ferulae Lanzi water extract of take is benchmark, the adult's (60Kg body weight) of take every day is standard, administration 0.0001 is to 100mg/kg, and in order to obtain better effect, more preferably administration 0.01 is to 10mg/kg.Administration number of times can be administered once for every day, also can be divided into multiple dosing.Above-mentioned dosage and administration number of times can not limit the present invention in any aspect.
By other embodiment of the present invention, provide a kind of contain Pleurotus ferulae Lanzi water extract as effective ingredient for improving the healthy functions food of hyperlipemia.In this description, " the healthy functions food " of indication refers to natural goods or the processed goods of the nutrient that contains one or more, preferably, forms the food of direct-edible state through processing technique to a certain degree.
The healthy functions food that adds Pleurotus ferulae Lanzi water extract of the present invention is such as can be various foodstuffs, beverage, chewing gum, tea, compound vitamin etc.In food of the present invention, can further comprise food of special nutrients (formula milk for example, baby, baby food etc.), finished meat products, fish product, Tofu, bean jelly class, Noodles (instant noodles series for example, such as noodles etc.), healthy accesary foods, (for example beans is oily for seasoned food, salty sauce, Fructus Capsici sauce, mix beans etc.), sauce class, Biscuits (for example puffed food class), breast processed goods (fermentation milk for example, cheese etc.), other processed food, Pickles, cure foods (various brined vegetable classes, pickles etc.), beverage (fruit for example, greengrocery beverage, soyabean milk class, fermented beverage class etc.), natural flavouring (such as condiment for instant noodles etc.), but be not limited to this.Above-mentioned food, beverage or food additive can be prepared by common preparation method.
In this description, functional food refers to methods such as utilizing physics, biochemistry, biological engineering, to food, gives added value and the food group that makes the function of described food work for specific purpose and bring into play; Or refer to that the health regulatory function about biophylactic entrainment, disease defence and recovery etc. that food composition is had designs, thereby the processed food that it is given full play to organism.Above-mentioned functions food can comprise in bromatology and to allow the food auxiliary additive that uses, and can further comprise and be generally used for suitable carrier, excipient and diluent prepared by functional food.
In this description, beverage refers to that it comprises functional beverage in order to remove thirsty or to taste the general name of the food that its taste drinks.Above-mentioned beverage is essential composition except the ratio with appointment contains, and Pleurotus ferulae Lanzi water extract, as outside effective ingredient, has no particular limits other compositions, and contain multiple scents or natural carbohydrate etc. the same as common beverage are as extra composition.Above-mentioned natural carbohydrate can be the common saccharides such as monosaccharide (such as glucose, fructose etc.), disaccharidase (such as maltose, sucrose etc.) and polysaccharide (dextrin, cyclodextrin etc.), and the sugar alcohol such as xylitol, sorbitol, erythritol.Except above-mentioned, as flavouring agent, can use natural flavours (rope is sweet, Stevia rebaudiana (Bertoni) Hemsl extract (such as vegetable baudy glucoside A, glycyrrhizin etc.)) and synthetic flavouring agent (glucide, aspartame etc.).It is benchmark that the ratio of above-mentioned natural carbohydrate be take the compositions of the present invention of every 100mL, is generally 1 to 20g, is preferably 5 to 12g.In addition, compositions of the present invention can further contain the sarcocarp for the preparation of natural fruit juice, fruit drink, vegetable beverage.
In addition, healthy functions food of the present invention can further contain flavoring agent, coloring agent and the modifying agents such as various nutrients, vitamin, mineral (electrolyte), synthetic flavoring agent and natural flavouring (
) the carbonic acid agent used in (cheese, chocolate etc.), pectic acid and its salt, alginic acid and its salt, organic acid, protective colloid thickening agent, pH adjusting agent, stabilizing agent, antiseptic, glycerol, water, soda pop etc.These compositions can be used alone or are used in combination.Although the ratio of above-mentioned additive is not particular importance, Pleurotus ferulae Lanzi water extract 100 weight portions of the present invention of take are benchmark, and the content of additive can be selected within the scope of 0 to 20 weight portion.
In this description, functional beverage refers to methods such as utilizing physics, biochemistry, biological engineering, to beverage, gives added value and makes the function of described beverage for the beverage group of its effect of specific purpose and performance; Or refer to that beverage is formed to the health regulatory function about biophylactic entrainment, disease defence and recovery etc. having to be designed, thereby the processing beverage that it is given full play to organism.
Above-mentioned functions beverage contains Pleurotus ferulae Lanzi water extract of the present invention as essential composition except usining the ratio of appointment, other compositions are had no particular limits, and contain multiple scents or natural carbohydrate etc. the same as common beverage are as extra composition.Above-mentioned natural carbohydrate can be the common saccharides such as monosaccharide (such as glucose, fructose etc.), disaccharidase (such as maltose, sucrose etc.) and polysaccharide (dextrin, cyclodextrin etc.), and the sugar alcohol such as xylitol, sorbitol, erythritol.Except above-mentioned, as flavouring agent, can use natural flavours (rope is sweet, Stevia rebaudiana (Bertoni) Hemsl extract (such as vegetable baudy glucoside A, glycyrrhizin etc.)) and synthetic flavouring agent (glucide, aspartame etc.).The ratio of above-mentioned natural carbohydrate, with the compositions benchmark of the present invention of every 100mL, is generally 1 to 20g, is preferably 5 to 12g.
And, take and improve or prevent in the healthy functions food that hyperlipemia is object, the amount of said extracted thing can be the content of 0.01 to 15 % by weight of food gross weight; And in beverage composition, take 100mL as benchmark, and said extracted thing content can be 0.02 to 5g, more preferably 0.3 to 1g.
And, according to another embodiment of the present invention, provide a kind of method of preparing the water extract of above-mentioned Pleurotus ferulae Lanzi.
The preparation method of the water extract of Pleurotus ferulae Lanzi according to an embodiment of the present invention comprises: the step of preparing Pleurotus ferulae Lanzi powder; The step that above-mentioned Pleurotus ferulae Lanzi powder is mixed with water; And to said mixture under 20 to 60 ℃ of temperature conditions, carry out the step of extracting for 12 to 36 hours.
Below, will, by specific embodiments of the invention, formation of the present invention and effect be described in further detail.Yet following embodiment is only that protection scope of the present invention is not limited by following embodiment for the clearer and more definite the present invention that understands.
And exceeding the powder of Pleurotus ferulae Lanzi of the present invention, inventor tests repeatedly found that the effect that does not suppress cholesteryl ester enzymatic activity, therefore now can think that it does not belong to protection scope of the present invention.
[embodiment] prepares the water extract of Pleurotus ferulae Lanzi
From market, buy dry Pleurotus ferulae Lanzi (Pleurotus eryngii var.ferulea (Pf.)), carry out after coarse powder, put in the sack of being made by tulle, every 1g powder of take is benchmark, add the water of 50mL to mix as extracting solvent, under 37 ℃ of conditions, in shaken cultivation machine, extract 24 hours.By the supernatant of shaken cultivation machine, with 2500rpm centrifugalize 10 minutes, then filter and collect supernatant, using it as test material.
[comparative example] prepares the water extract of Pleurotus ferulae Lanzi
Use respectively the water of 70% and 100% ethanol (99.9% (v/v)) the replacement 50mL of 100mL, as extracting outside solvent use, by method same as the previously described embodiments, under more than 65 ℃ temperature conditions, the alcohol reflux thing of preparing Pleurotus ferulae Lanzi, using it as test material.
< test example 1>
the pancreatic cholesterol esterase activity of Pleurotus ferulae Lanzi extract according to the present invention measure
Pancreatic cholesterol esterase is non-specific identification to have the substrate of acyl chain (acyl chain), and brings into play the function of separated acyl chain.In order to measure according to the activity of the pancreatic cholesterol esterase of the Pleurotus ferulae Lanzi extract of embodiment and comparative example, the pig pancreatic cholesterol esterase that uses sigma chemical company (Sigma chemical co., Ltd) to prepare as enzyme.
Utilize the character of pancreatic cholesterol esterase decomposition chromogenic substrate (chromo-genic substrate) (p-nitrophenyl butyrate (p-nirophenylbutyrate)), by chromogenic reaction, confirmed the activity change of enzyme.Utilize microplate reader (microplate reader) to detect the absorbance at 405nm place, thus the active inhibition of mensuration enzyme, and the 405nm place absorbance of the non-processed group of extract of usining calculates as benchmark, and represents with %.
Measured according to the enzymatic activity of embodiment and comparative example and changed, the water extract of results verification embodiment significantly reduces the activity of pancreatic cholesterol esterase.
And 70% and 100% ethanol extraction matter sample of comparative example does not almost show the active effect that suppresses pancreatic cholesterol esterase.In Fig. 1, simply show experimental result, and compare.
< test example 2>
according to the pancreatic cholesterol esterase activity of Pleurotus ferulae Lanzi water extract concentration measure
In addition, measured the pancreatic cholesterol esterase activity according to the water extract concentration of the Pleurotus ferulae Lanzi of embodiment.The amount of the Pleurotus ferulae Lanzi water extract that pancreatic cholesterol esterase is processed, the extraction initial stage Pleurotus ferulae Lanzi powder concn of take is benchmark (1%), while diluting 1/5 times, 1/10 times, 1/50 times, the effect that it is suppressed to pancreatic cholesterol esterase activity compares, and comparative result as shown in Figure 2.
< test example 3>
according to the mensuration of the pancreas lipase active of Pleurotus ferulae Lanzi water extract concentration
Pancreas lipase is non-specific identification to have the substrate of acyl chain, and brings into play the function of separated acyl chain.In order to measure according to the pancreas lipase active of the Pleurotus ferulae Lanzi extract of the embodiment of variable concentrations, the porcine pancreatic lipase that uses sigma chemical company (Sigma chemical co., Ltd) to prepare as enzyme.
Utilize the character of pancreas lipase decomposition chromogenic substrate (p-nitrobenzophenone butyrate), by chromogenic reaction, confirmed the activity change of enzyme.Utilize microplate reader to detect the absorbance at 405nm place, thus the active inhibition of mensuration enzyme, and the 405nm place absorbance of the non-processed group of extract of usining calculates as benchmark, and represents with %.
Measured according to the activity change of the enzyme of the concentration of the Pleurotus ferulae Lanzi water extract of embodiment, results verification the Pleurotus ferulae Lanzi water extract concentration dependent ground of embodiment significantly reduce the activity of pancreas lipase.In Fig. 3, simply show its result.
< test example 4>
the mensuration of the cholesterol absorption of Pleurotus ferulae Lanzi water extract according to the present invention
In order to confirm to show the Pleurotus ferulae Lanzi water extract with the embodiment that suppresses cholesteryl ester enzymatic activity effect, in individual level, whether also there is effect, measured in gastral cholesterol absorption.
Will with isotopic element (
3h) cholesterol acid ester of labelling (Cholesterol oleate, An Ma West Asia company, 100 μ Ci/ml) mix with 1% (w/v) sodium carboxymethyl cellulose (CMC-Na), 1% (v/v) Tween 80 (Tween80), unlabelled cholesterol acid ester, by irrigation stomach device (
) force administration 0.1mL to every mice, make to inject 1 μ Ci to every.
Wherein, give the orlistat that suppresses cholesterol absorption function that has of 400 μ g (20mg/kg) to control group mice (Balb/c is male, 8 week age, the about 25g of body weight); And for experimental mice (Balb/c is male, 8 week age, the about 25g of body weight), concentrate the Pleurotus ferulae Lanzi water extract (10mg/mL) of the embodiment of 20mL, by its oral administration 1mL to above-mentioned experimental mice.
After 6 hours, gather the blood of mice, under 4 ℃ of conditions, with 14000rpm centrifugal 10 minutes, thus the separated blood plasma that obtains, utilize liquid scintillation counter (Beta counter, Beckman LS1801) measure dosage (
).Matched group is not for giving the group of any cholesterol absorption inhibitor.The dosage of matched group is made as 1, and the relative value by the dosage of each experimental group during divided by the dosage of matched group is set as fat absorption amount.
Pleurotus ferulae Lanzi water extract according to the present invention is the same with the orlistat using as a control group, has demonstrated the effect of significant inhibition fat absorption.At Fig. 4, shown its result, and compared.As a reference, the contrast in Fig. 4 (control) is not for giving the blood sampling result of the mice of any cholesterol absorption inhibitor.
Below, recorded the example using Pleurotus ferulae Lanzi water extract of the present invention as the various dosage forms of effective ingredient, but dosage form of the present invention is not limited in this.
preparation example 1.the preparation of powder
Pleurotus ferulae Lanzi water extract powder 20mg
Lactose 100mg
Talcum 10mg
Mentioned component is mixed, be filled to airtight bag, thereby be prepared into powder.
preparation example 2.the preparation of tablet
Pleurotus ferulae Lanzi water extract powder 10mg
Corn starch 100mg
Lactose 100mg
Magnesium stearate 2mg
Mix after mentioned component, according to common method for preparing tablet thereof, carry out tabletting and be prepared into tablet.
preparation example 3.the preparation of capsule
Pleurotus ferulae Lanzi water extract powder 10mg
Crystallinity cellulose 3mg
Lactose 14.8mg
Magnesium stearate 0.2mg
According to common capsule preparation method thereof, mix mentioned component, be filled in gelatine capsule, thereby be prepared into capsule.
preparation example 4.the preparation of liquor
Pleurotus ferulae Lanzi water extract powder 20mg
Isomerized sugar 10g
Mannitol 5g
Pure water is appropriate
According to common liquor preparation method, to pure water, add respectively above-mentioned each composition and dissolve, and mixing mentioned component after adding in right amount lemon flavouring, add afterwards pure water and be adjusted to after 100mL, be filled to brown bottle, sterilizing, thus be prepared into liquor.
preparation example 5. the preparation of injection
Pleurotus ferulae Lanzi water extract powder 10mg
Mannitol 180mg
Injection sterile purified water 3000mg
Na
2HPO
4·12H
2O?25mg
According to the preparation method of common injection, being prepared in each ampoule (2mL) is mentioned component and content.
preparation example 6. the preparation of health food
Pleurotus ferulae Lanzi water extract powder 1000mg
Vitamin mixtures is appropriate
Vitamin A acetate 70 μ g
Vitamin E 1.0mg
Vitamin B1 0.13mg
Vitamin B2 0.15mg
Vitamin B6 0.5mg
Vitamin B12 0.2 μ g
Vitamin C 10mg
Biotin 10 μ g
Nicotiamide 1.7mg
Folic acid 50 μ g
Calcium pantothenate 0.5mg
Mineral mixture is appropriate
Ferrous sulfate 1.75mg
Zinc oxide 0.82mg
Magnesium carbonate 25.3mg
Potassium dihydrogen phosphate 15mg
Calcium hydrogen phosphate 55mg
Potassium citrate 90mg
Calcium carbonate 100mg
Magnesium chloride 24.8mg
Above-mentioned vitamin and the proportion of composing of mineral mixture are by the composition than being more suitable for health food, mix, but can be out of shape arbitrarily its proportioning as preferred embodiment.After mentioned component being mixed according to the method for conventionally preparing health food, be prepared into granule, it can be used for by usual way the preparation of health food composition.
Claims (8)
1. for preventing or treat a compositions for hyperlipemia, it is characterized in that, its water extract that contains Pleurotus ferulae Lanzi is as effective ingredient.
2. compositions according to claim 1, is characterized in that, described water extract be by Pleurotus ferulae Lanzi in the water of the temperature of 20 to 60 ℃, the extraction of carrying out 12 to 36 hours obtains.
3. compositions according to claim 1, is characterized in that, described water extract is mix 1 to 5g Pleurotus ferulae Lanzi powder and extract in the water of every 50mL.
4. compositions according to claim 1, is characterized in that, the content of the water extract of described Pleurotus ferulae Lanzi is 0.01 to 30 % by weight.
5. for preventing or treat a pharmaceutical composition for hyperlipemia, it is characterized in that, its water extract that contains Pleurotus ferulae Lanzi is as effective ingredient.
6. pharmaceutical composition according to claim 5, is characterized in that, described pharmaceutical composition is any medicine being selected from powder, granule, tablet, suspending agent, Emulsion, injection or syrup.
7. a functional health accesary foods compositions of improving hyperlipemia, is characterized in that, its water extract that contains Pleurotus ferulae Lanzi is as effective ingredient.
8. the functional health accesary foods compositions of improving hyperlipemia according to claim 7, is characterized in that, described healthy accesary foods compositions is to be selected from any in food, food additive or beverage.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0132728 | 2011-12-12 | ||
| KR20110132728 | 2011-12-12 | ||
| KR1020120143701A KR101565964B1 (en) | 2011-12-12 | 2012-12-11 | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia |
| KR10-2012-0143701 | 2012-12-11 | ||
| PCT/KR2012/010792 WO2013089429A1 (en) | 2011-12-12 | 2012-12-12 | Composition for preventing or treating hyperlipidemia containing water extract of pleurotus eryngii var. ferulae as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104023734A true CN104023734A (en) | 2014-09-03 |
Family
ID=48862761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280061440.7A Pending CN104023734A (en) | 2011-12-12 | 2012-12-12 | Composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as active ingredient |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2015502954A (en) |
| KR (1) | KR101565964B1 (en) |
| CN (1) | CN104023734A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107613998A (en) * | 2015-05-27 | 2018-01-19 | 庆尚北道 | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101634200B1 (en) * | 2014-05-22 | 2016-07-11 | 포항공과대학교 산학협력단 | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Bjerkandera adusta. FOR TREATING OR PREVENTING HYPERLIPIDEMIA |
| KR101706516B1 (en) * | 2016-12-14 | 2017-02-15 | 포항공과대학교 산학협력단 | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING OBESITY |
| KR102624698B1 (en) * | 2022-05-23 | 2024-01-12 | 하송윤 | A manufacturing method of functional drinking water additive |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161842A1 (en) * | 2001-12-20 | 2003-08-28 | Rui Wang | Pleurotus extract and use in treating hypertension |
| CN101164452A (en) * | 2006-10-17 | 2008-04-23 | 天津科技大学 | Double-preparation type composite mushroom functional beverage host and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372462B2 (en) * | 1999-10-15 | 2002-04-16 | Medmyco Ltd. | Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms |
| JP2002087981A (en) | 2000-07-11 | 2002-03-27 | Hitoshi Nagaoka | Improving agent for metabolic disorder against sugar and lipid |
| JP5563824B2 (en) * | 2007-10-24 | 2014-07-30 | サントリーホールディングス株式会社 | Peroxisome proliferator-responsive receptor (PPAR) ligand agent |
| CN101914168B (en) * | 2010-09-06 | 2013-06-19 | 石河子大学 | Medical applications and preparation methods of Pleurotus ferulae Lanzi polysaccharide and composites thereof |
-
2012
- 2012-12-11 KR KR1020120143701A patent/KR101565964B1/en active IP Right Grant
- 2012-12-12 CN CN201280061440.7A patent/CN104023734A/en active Pending
- 2012-12-12 JP JP2014545832A patent/JP2015502954A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161842A1 (en) * | 2001-12-20 | 2003-08-28 | Rui Wang | Pleurotus extract and use in treating hypertension |
| CN101164452A (en) * | 2006-10-17 | 2008-04-23 | 天津科技大学 | Double-preparation type composite mushroom functional beverage host and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| NUHU ALAM ET AL.: "Antihyperlipidemic activities of Pleurotus ferulae on biochemical and histological function in hypercholesterolemic rats", 《JRMS》 * |
| 冯作山等: "阿魏对阿魏菇子实体抗氧化性能及氨基酸组成的影响", 《中国食品学报》 * |
| 黄文书等: "阿魏菇提取物对红细胞过氧化损伤的影响", 《食品工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107613998A (en) * | 2015-05-27 | 2018-01-19 | 庆尚北道 | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130066535A (en) | 2013-06-20 |
| KR101565964B1 (en) | 2015-11-16 |
| JP2015502954A (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101490786B1 (en) | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity | |
| JPWO2015046486A1 (en) | Obesity suppressing composition | |
| CN104023734A (en) | Composition for preventing or treating hyperlipedemia containing a water extract of Pleurotus eryngii var. ferulae as active ingredient | |
| JP2018516987A (en) | Pharmaceutical composition or health functional food for prevention and treatment of metabolic disease containing water extract of Aso as active ingredient | |
| KR101490781B1 (en) | Composition comprsing alcohol extracts from albatrellus dispansus for treating or preventing hyperlipidemia | |
| KR101490794B1 (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia | |
| KR101594649B1 (en) | Composition comprising alcohol extracts from ramaria stricta for treating or preventing hyperlipidemia | |
| KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
| KR101691256B1 (en) | COMPOSITION COMPRISING ALCOHOL EXTRACTS FROM Oligoporus stipticus, FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
| KR20150048698A (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR101490800B1 (en) | Composition comprising water extracts from laetiporus sulphureus var. miniatus (jungh.) imaz. for treating or preventing hyperlipidemia | |
| KR101490792B1 (en) | Composition comprsing alcohol extracts from hapalopilus rutilans for treating or preventing obesity | |
| KR101706516B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING OBESITY | |
| KR20120126749A (en) | Composition Comprising Alcohol Extracts from Sparassis cripspa Wulfen Fr. for Treating or Preventing Obesity | |
| KR101625280B1 (en) | COMPOSITION COMPRSING ALCOHOL EXRACTS FROM Albatrellus fletti FOR TREATING OR PREVENTING OBESITY | |
| KR101598668B1 (en) | Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia | |
| KR101706431B1 (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM Lactarius Volemus FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
| KR101773221B1 (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia | |
| KR101626191B1 (en) | Composition comprising water extracts from suillus bovinus for treating or preventing hyperlipidemia | |
| KR101569254B1 (en) | composition comprising water extracts from oudemansiella platyphylla for treating or preventing hyperlipidemia | |
| CN110234333A (en) | Using fructus lycii, mulberries and jujube for enhancing immune composition, composition for preventing or treating degenerative neurological diseases | |
| KR20190015423A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulae (Pf.). for treating or preventing metabolic disorder | |
| KR20170116597A (en) | COMPOSITION COMPRISING WATER EXTRACTS FROM pleurotus cornucopiae(paulet) Rolland FOR TREATING OR PREVENTING HYPERLIPIDEMIA | |
| KR20160104590A (en) | Composition comprising alcohol extracts from russula japonica for treating or preventing hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140903 |